TYPE 2 DIABETES MELLITUS AND PRION PROTEINS

CO-RELATION OF AMYLIN AND AMYLOID FIBRILS WITH TYPE 2 DIABETES MELLITUS AND ITS ASSOCIATION WITH PRION PROTEINS AND LOW DOSE DOXYCYCLINE ROLE IN LOWERING THE GLYCEMIC INDEX - AN UNICENTRIC, DOUBLE BLINDED, RANDOMIZED CONTROLLED TRIAL - nil

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/11/097697

Enrollment

100

Registered

2025-11-19

Start date

Unknown

Completion date

Unknown

Last updated

2025-12-08

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: E119- Type 2 diabetes mellitus without complications

Interventions

Intervention1: Doxycycline: T2 DM with doxycycline 500 mg twice daily for 1 month Control Intervention1: Without doxycycline: T2 DM without doxycycline

Eligibility

Inclusion criteria

Inclusion criteria: Diagnosed with Type 2 Diabetes Mellitus FBS, PPBS, HbA1c AS PER ADA Guidelines for type 2 DM Ability to provide informed consent.

Exclusion criteria

Exclusion criteria: Presence of type 1 diabetes or gestational diabetes Severe renal insufficiency Uncontrolled cardiovascular disease or neurodegenerative disorder Pregnant or breast feeding woman Other autoimmune disorder Amyloidosis other than IAPP

Design outcomes

Primary

Measure	Time frame
Correlation between amylin levels and amyloid fibril deposition in the pancreasTimepoint: On day 0, and end of 1, 2, 3, and 6 months	—

Secondary

Measure	Time frame
Glycemic control C-peptide levels Prion proteinsTimepoint: At the end of 6 and 12 months	—

Countries

India

Contacts

Public ContactDR Madhan Jeyaraman

Sri Lalithambigai Medical College and Hospital, Dr MGR Educational and Research Institute

madhanjeyaraman@gmail.com8310600785

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026